Selection of Optimal Therapy at Correction of the Anemic Syndrome in Patients With Chronic Heart Failure

Purpose: to study efficacy of various schemes of therapy of patients with chronic heart failure (CHF) and anemia. Materials and methods. We included in this study 208 patients with CHF of ishemic etiology (mean age 60.6±1.4 years, 174 with and 34 without anemia). According to therapeutic regimen of the use of methoxy polyethylene glycol-epoetin beta (MEB, 0.60 mсg/kg) and intravenous (IV) iron hydroxide sucrose complex all patients were divided into 4 groups. In all patients before and after treatment we determined Hb, Ht, plasma levels of ferritin, erythropoietin (EPO), NT-proBNP, IL-1, IL-6, TNF-a, transferrin saturation (TS), total vascular peripheral resistance, and parameters of systolic and diastolic function of left ventricular (LV) myocardium (by echocardiography and doppler echocardiography). Results. In patients with NYHA class I-IV CHF and anemia increases of Hb, Ht, TS, levels of EPO and ferritin occurred during treatment by basic drugs combained with MEB. In subgroups of patients with NYHA class I-II and III-IV the 6-minute walk distance significantly increased by 25.1 and 38.3%, and GFR- by 24.5 and 14.9%, respectively. At the background of therapy with IV iron we observed significant increases of Hb, plasma level of ferritin, and TS. Combined treatment with MEB and IV iron was associated with positive dynamics of Hb, Ht, levels of ferritin, EPO, NT-proBNP, and IL-6. In this group in subgroups of patients with NYHA class I-II and III-IV the 6-minute walk distance significantly increased by 21.6 (p<0.001) and 64.9% (p<0.001), respectively. Conclusion. In the treatment of patients with CHF with anemia there is a need for differentiaion depending on such parameters as plasma levels of ferritin, EPO, and TS. In patients with CHF and anemia combined therapy with MEB and IV iron promotes significant positive dynamics of Hb, ferritin, TS and EPO, as well as of LV myocardial function parameters.

хроническая сердечная недостаточность, анемия, кардиоренальный синдром, ферритин, эритропоэтин, цитокины, chronic heart failure, anemia, cardiorenal syndrome, ferritin, erythropoetin, cytokines

1. Go A. S., Mozaffarian D., Roger V. L. et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6.

2. Агеев Ф. Т., Арутюнов Г. П., Беленков Ю. Н. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа 2010; 336

3. Anand I. S. Heart failure and anaemia: mechanisms and pathophisi-ology. Heart Fail Rev 2008; 13: 379-386.

4. Mozaffarian D., Nye R., Levy W. C. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J. Am Coll Cardiol 2003; 41 (11): 1933-1939.

5. Ezekowitz J. A., McAlister F. A., Armstrong P. W. Anemia is common in heart failure and is associated with poor outcomes. Circulation 2003; 21 (2): 23-225.

6. Arora N. P., Ghali J. K. Iron deficiency anemia in heart failure. Heart Fail Rev. 2013; 18 (4): 485-501. doi: 10.1007/s10741-012-9342-y.

7. Lewis B. C., Karabi B., Jaffe R. et al. Anemia and heart failure: statement of the problem. Nephrol Dial Translant2005; 20 (sup-pl. 7): VII 3 - VII 6. doi: 10.1093-1099.

8. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J. 2005; 149 (3): 391-401.

9. SOLVD - Trial, Yusuf S. et al. Effect ofEnalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. The New EnglJ Med 1991; 325 (5): 293-302.

10. Solomon S. D., Wang D., Finn P. Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program. Circulation 2004; 110: 2180-2183.

11. Kannel W. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J. 1987; 8 (Suppl. F): 23-29.

12. Knight E. L., Glynn R.J., Mclntyre K. M. et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies Of Left Ventricular Dysfunction (SOLVD): Am Heart J. 1999; 138: 849-855.

13. Шалаев С.В., Волкова С. Ю. Прогностическое значение уровней в плазме N-концевого фрагмента мозгового натрийуретического пропептида и провоспалительных цитокинов у больных сердечной недостаточностью ишемической этиологии. Кардиология 2009; 10: 22-26

14. Tanimura M., Dohi K., Fujimoto N. et al. Effect of Anemia on Cardiovascular Hemodynamics, Therapeutic Strategy and Clinical Outcomes in Patients With Heart Failure and Hemodynamic Congestion. Circ J. 2017. doi: 10.1253/circj.CJ-17-0171.

15. Silverberg D. S., Wexler D., Blum M., Iaina A. The cardio-renal-ane-mia sydrome. Correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 2003; 60 Suppl 1S: 93-102.

16. Komajda M. Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J. Card Fail 2004; 10: S1-4.

17. Horwich T. B., Fonarow G. C., Hamilton M. A. et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am Coll Cardiol 2002; 39: 17806.

18. Kaldara-Papatheodorou E. E., Terrovitis J. V., Nanas J. N. Anemia in heart failure: should we supplement iron in patients with chronic heart failure? Pol Arch Med Wewn 2010; 120 (9): 354-360.

19. Anker S. D., Haehling von S. Anaemia in chronic heart failure. Bremen: UNI-MED. 2009; 79: 39-40.

20. Mancini D. M., Katz S. D., Lang C. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-299.

21. Parissis J. T., Korea K., Panou F. et al. Effect of Darbepoetin alpha onright and levt ventricular systolic and diastolic function in anaemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am Heart J. 2008; 155: 751-757.

22. Van der Meer P., Lipsic E., van Gilst W. H. et al. Anemia and erythropoietin in heart failure. Heart Fail Monit 2008; 6 (1): 28-33.

23. Palazuolli A., Silverberg D., Iovine F. et al. Effect of beta erythropoietin treatment of left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anaemia syndrome. Am Heart J. 2007; 154: 645. e9-645. e15.

24. Ponikowski P., Anker S. D., Szachniewicz J. et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J. Am Coll Cardiol 2007; 20: 49 (7): 753-762.

25. Ghali J. K., Anand I. S., Abraham W. T. et al. Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 29: 117 (4): 526-535.

26. McMurray J. J., Anand I. S., Dias R. et al. Design of the reduction of Events With Darbopoietin Alfa in Heart Failure (RED-HF): a Phase III, anemia correction, morbidity-mortality trial. Eur J. Heart Fail 2009; 11 (8): 795-801.

27. Comin-Colet J., Ruiz S., Cladellas M. et al. A pilot evaluation of the longterm effect of combined therapy with intravenous iron sucrose and erythropoietin for the in elderly patients with advanced chronic heart failure and cardiorenal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J. Card Fail 2009; 15: 727-735.

28. Sulowicz W., Locatelli F., Ryckenlynck J.-P. et al. On behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoietin one to three times weekly. Clin J. Am Soc Nephrol 2007; 2: 637-646.

29. Klinger M., Arias M., Vargemezis V. et al. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals correct Hb levels in patients with CKD on dialysis. J. Am Sos Nephrol 2006; 17: 620A.

30. Ngo K., Kotecha D., Walters J. A. et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010; (1): CD007613.

31. Toblli J. E., Lombrana A., Duarte P. et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J. Am Coll Cardiol 2007; 50: 1657-1665.

32. Okonko D. O., Grzeslo A., Witkowski T. еt al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled observer-blinded trial. J. Am Coll Cardiol 2008; 51 (2): 103-12.

33. Beck-da-Silva L., Piardi D., Soder S. et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J. Cardiol 2013; 168 (4): 3439-3442.

34. Silverberg D. S., Wexler D., Iaina A. T. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J. Nephrol 2004; 17 (6): 749-761.

35. Bolger A. P., Bartlett F. R., Penston H. S. et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J. Am Coll Cardiol 2006; 48 (6): 1225-1227.

36. Usmanov R. I., Zueva E. B., Silverberg D. S. et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J. Nephrol 2008; 21 (2): 236-242.

37. Drakos S. G., Anastasiou-Nana M. I., Malliaras K. G. et al. Anemia in chronic heart failure. Congest Heart Fail 2009; 15 (2): 87-92.

38. Silverberg D. S., Weksler D., Blum M. et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol 2002; 58 (Suppl 1): S37-S45.